0001127602-24-009368.txt : 20240311
0001127602-24-009368.hdr.sgml : 20240311
20240311160832
ACCESSION NUMBER: 0001127602-24-009368
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240308
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Deschatelets Pascal
CENTRAL INDEX KEY: 0001657720
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 24738037
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-03-08
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001657720
Deschatelets Pascal
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
Chief Scientific Officer
1
Common Stock
2024-03-08
4
M
0
69107
3.67
A
1185090
D
Common Stock
2024-03-08
4
S
0
42750
61.8754
D
1142340
D
Common Stock
2024-03-08
4
S
0
26257
62.6896
D
1116083
D
Common Stock
2024-03-08
4
S
0
100
63.35
D
1115983
D
Stock Option (Right to Buy)
3.76
2024-03-08
4
M
0
69107
0
D
2026-02-07
Common Stock
69107
106387
D
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This transaction was executed in multiple trades at prices ranging from $61.30 - $62.295. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This transaction was executed in multiple trades at prices ranging from $62.30 - $63.2925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023.
This stock option was granted on 02/08/2016 and is fully vested.
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
2024-03-11